Cucurbit[n]uril type hosts for the reversal of steroidal neuromuscular blocking agents

Future Medicinal Chemistry

Volumn 5, Issue 17, 2013, Pages 2075-2089

  Macartney, Donal H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ATRACURIUM BESILATE; CHOLINESTERASE INHIBITOR; CUCURBITURIL; CYCLODEXTRIN; GANTACURIUM; MIVACURIUM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; NEUROMUSCULAR DEPOLARIZING AGENT; NICOTINIC RECEPTOR; PANCURONIUM; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VECURONIUM;

BINDING AFFINITY; BINDING COMPETITION; COVALENT BOND; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENCAPSULATION; HUMAN; MUSCLE CONTRACTION; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

ANIMALS; CHOLINESTERASE INHIBITORS; CYCLODEXTRINS; DRUG CARRIERS; GAMMA-CYCLODEXTRINS; HUMANS; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; NEUROMUSCULAR BLOCKING AGENTS;

EID: 84887986648     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.164     Document Type: Review

References (97)

1. Dawson J, Jones M. The principles of anaesthesia. Surgery 31(2), 67-71 (2012).
2. Mirakhur RK. Neuromuscular Blocking and Reversal Agents. In: Pharmacology for Anaesthesiologists. Fee JPH, Bovill JG (Eds). Taylor & Francis, FL, USA, 94-104 (2005).
3. Naguib M, Brull SJ Pharmacology of Neuromuscular Blockers. In: Neuroscientific Foundations of Anesthesiology. Mashour GA, Lydic R (Eds). Oxford University Press, London, UK, 211-230 (2011).
4. Lien CA, Eikermann M. Neuromuscular Blockers and Reversal Drugs. In: Pharmacology and Physiology for Anesthesia Hemmings HC, Egan TD (Eds). Saunders, MO, USA, 325-348 (2013).
5. Hughes BW, Kusner LL, Kamiski HJ Molecular architecture of the neuromuscular junction. Muscle Nerve 33(4), 445-461 (2006).
6. Lee C. Conformation, action, and mechanism of action of neuromuscular blocking muscle relaxants. Pharmacol. Ther. 98(2), 143-169 (2003). (Pubitemid 36513773)
7. Martyn JA, Fagerlund MJ, Eriksson, LI. Basic principles of neuromuscular transmission. Anesthesia 64(Suppl. 1), 1-9 (2009).
8. Lien CA. Development and potential clinical impact of ultra-short acting neuromuscular blocking agents. Br. J. Anaesth. 107(Suppl. 1), i60-i70 (2011).
9. Srivastava A, Hunter JM Reversal of neuromuscular block. Br. J. Anaesth. 103(1), 115-129 (2009).
10. Caldwell JE. Clinical limitations of acetylcholinesterase antagonists. J. Crit. Care 24(1), 21-28 (2009).
11. Cameron KS, Fielding L, Mason R et al. Anionic cyclophanes as potential reversal agents of muscle relaxants by chemical chelation. Bioorg. Med. Chem. Lett. 12(5), 753-755 (2002). (Pubitemid 34164611)
12. Tarver GJ, Grove SJA, Buchanan K et al. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg. Med. Chem. 10(6), 1819-1827 (2002). (Pubitemid 34286374)
13. Adams JM, Bennett DJ, Bom A et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J. Med. Chem. 45(9), 1806-1816 (2002). (Pubitemid 34415376)
14. Bom A, Bradley M, Cameron K et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew. Chem. Int. Ed. 41(2), 266-279 (2002).
15. Nitalika MM, Sakarkar DM, Jain PV The Cyclodextrins: a review. J. Curr. Pharm. Res. 10(1) 1-6 (2012).
16. Sikharam S, Egan TD, Kern SE Cyclodextrins as new formulation entities and therapeutic agents. Curr. Opin. Anaesthesiol. 18(4), 392-395 (2005). (Pubitemid 41073135)
17. Reddy PC, Chaitanya CKS, Subrahmanyam PVRS, Rao YM. Cyclodextrins and their derivatives in drug delivery: a review. Curr. Trends Biotech. Pharm. 6(3), 255-275 (2012).
18. Loftsson T, Brewster ME Drug Solubilization And Stabilization By Cyclodextrin Drug Carriers. In: Drug Delivery Strategies for Poorly Water-Soluble Drugs. Douroumis D, Fahr A (Eds). John Wiley and Sons Ltd, Oxford, UK, 67-101 (2013).
19. Cooper A, Nutley M, MacLean EJ et al. Mutual induced fit in cyclodextrin-rocuronium complexes. Org. Biomol. Chem. 3(10), 1863-1871 (2005). (Pubitemid 40751357)
20. Cameron KS, Fletcher D, Fielding L. An NMR study of cyclodextrin complexes of the steroidal neuromuscular blocker drug rocuronium bromide. Mag. Res. Chem. 40(4), 251-260 (2002). (Pubitemid 37282032)
21. Zwiers A, Van Der Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex. Clin. Drug Investig. 31(2), 101-111 (2011).
22. Ma D, Zhang B, Hoffmann U et al. Acyclic cucurbit[n]uril-type molecular containers bind neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo. Angew. Chem. Int. Ed. 51(45), 11358-11362 (2012).
23. Kwok JC. Cucurbit[7]uril host-guest complexes with drug molecules containing isoquinoline groups. MSc. Thesis, Queen's University, Kingston, UK (2011).
24. Wyman I.W., Macartney DH Cucurbit[7]uril host-guest complexes of cholines and phosphonium cholines in aqueous solution. Org. Biomol. Chem. 8(1), 253-260 (2010).
25. Glassenberg R. Alternative neuromuscular blocker chelators. Presented at: Anesthesiology 2009. LA, USA, 17-21 October 2009.
26. De Kam P.J., Cavens L, Van der Heuvel M et al. Flucoxacillin and diclofenac do not cause reoccurrence of blockade after reversal with sugammadex. Presented at: Anesthesiology 2009. LA, USA, 17-21 October 2009.
27. Gijsenbergh F, Ramael S, Houwing N., van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 103(4), 695-703 (2005). (Pubitemid 41415517)
28. Cammu G, De Kam PJ, Demeyer I et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br. J. Anaesth. 100(3), 373-393 (2008).
29. -1 are not associated with Qt/QTc prolongation. Anesthesiology 107, A1580 (2007).
30. Shields M, Giovannelli M, Mirakhur R.K., Moppett I., Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br. J. Anaesth. 96(1), 36-43 (2006). (Pubitemid 43124528)
31. Suy K, Morias K, Cammu G et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 106(2), 283-288 (2007). (Pubitemid 46185173)
32. Pühringer F.K., Rex C, Sielenkämper AW et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, Phase II trial. Anesthesiology 109(2), 188-197(2008).
33. -1) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 107(2), 239-244 (2007). (Pubitemid 47196486)
34. Groudine SB, Soto R, Lien C., Drover D, Robert K. A randomized, dose-finding, Phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium induced neuromuscular block. Anesth. Analg. 104(1), 55-62 (2007).
35. Blobner M, Eriksson L, Scholz J., Hillebrand H, Pompei L. Sugammadex (2.0 mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50 μg/kg). Eur. J. Anaesthesiol. 24(Suppl. 39), 125 (2007).
36. Jones RK, Caldwell JE, Brull S.J., Soto RG Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 109(5), 816-824 (2008).
37. Lemmens HJM, El-Orbany MI, Berry J., Martin G. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine [abstract]. American Society of Anesthesiologists. 107, Abstract 1578. (2007).
38. Lee C, Jahr JS, Candiotti K, Warriner B., Zornow MH Reversal of profound rocuronium NMB with sugammadex is faster than recovery from succinylcholine. Anesthesiology 107, A988 (2007).
39. Bisschops MMA, Holleman C, Huitink JM Can sugammadex save a patient in a simulated 'cannot intubate, cannot ventilate' situation? Anaesthesia 65(9), 936-941 (2010).
40. Yang LPH, Keam SJ Sugammadex. A review of its use in anaesthetic practice. Drugs 69(7), 919-942 (2009).
41. Bom A, Hope F, Rutherford S., Thompson K. Preclinical pharmacology of sugammadex. J. Crit. Care 24(1), 29-35 (2009).
42. Lee C, Jahr JS, Candiotti KA et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium. Anesthesiology 110(5), 1020-1025 (2009).
43. Akha AS, Rosa III J, Jahr JS et al. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Anesthesiol. Clin. 28(4), 691-708 (2010).
44. Blobner M, Eriksson LI, Scholz J, Motsch J., Della Rocca G, Prins ME Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur. J. Anaesthesiol. 27(10), 874-881 (2010)
45. Suzuki T, Kitajima O, Ueda K., Kondo Y, Kato J, Ogawa S. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients. Br. J. Anaesth. 106(6), 823-826 (2011).
46. McDonnell NJ, Pavy TJG, Green LK, Platt PR Sugammadex in the management of rocuronium-induced anaphylaxis. Br. J. Anaesth. 106(2), 199-201 (2011).
47. Lagona J, Mukhopadhyay P, Chakrabarti S., Isaacs L. The cucurbit[n]uril family. Angew. Chem. Int. Ed. 44(31), 4844-4870 (2005). (Pubitemid 41138666)
48. Masson E, Ling X, Joseph R et al. Cucurbituril chemistry: a tale of supramolecular success. RSC Adv. 2(4), 1213-1247 (2012).
49. Kim K, Selvapalam N, Ko YH et al. Functionalized cucurbiturils and their applications. Chem. Soc. Rev. 36(2), 267-279 (2007).
50. Pemberton BC, Raghunathan R, Volla S., Sivaguru J. Container to catalysts: supramolecular catalysis within cucurbiturils. Chem. Eur. J. 18(39), 12178-12190 (2012).
51. Urbach AR, Ramalingam V. Molecular recognition of amino acids, peptides, and proteins by cucurbit[n]uril receptors. Isr. J. Chem. 51(5-6), 664-678 (2011).
52. Macartney DH. Encapsulation of drug molecules by cucurbiturils: effects on their chemistry properties in aqueous solution. Isr. J. Chem. 51(5-6), 600-615 (2011).
53. Walker S, Oun R, McInnes FJ, Wheate NJ, The potential of cucurbit[n]urils in drug delivery. Isr. J. Chem. 51(5-6), 616-624 (2011).
54. a shifts to enhance the bioavailability of drugs. Adv. Drug Deliv. Rev. 64(9), 764-783 (2012).
55. Wheate NJ, Buck DP, Day A.I., Collins JG Cucurbit[n]uril binding of platinum anticancer complexes. Dalton Trans. (3), 451-458 (2006).
56. Uzunova VD, Cullinane C, Brix K et al. Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study. Org. Biomol. Chem. 8(12), 2037-2042 (2010).
57. Hettiarachchi G, Nguyen D, Wu J et al. Toxicology and drug delivery by cucurbit[n]uril type molecular containers. PLoS ONE 5(5), e10514 (2010).
58. Montes-Navajas P., Gonzales-Bejar M, Scaiano J.C., Garcia H. Cucurbituril complexes cross the cell membrane. Photochem. Photobiol. Sci. 8(12), 1743-1747 (2009).
59. St-Jacques A.D., Wyman I W, Macartney DH Encapsulation of charge-diffuse peralkylated onium cations in the cavity of cucurbit[7]uril. Chem. Commun. 40, 4936-4938 (2008).
60. Wyman IW, Macartney DH Host-guest complexes and pseudorotaxanes of cucurbit[7]uril with acetylcholinesterase inhibitors. J. Org. Chem. 74(21), 8031-8038 (2009).
61. Wyman IW, Macartney DH Host-guest complexations of local anaesthetics by cucurbit[7]uril in aqueous solution. Org. Biomol. Chem. 8(1), 247-252 (2010).
62. Gamal-Eldin M.A., Macartney DH Selective molecular recognition of methylated lysines and arginines by cucurbit[6]uril and cucurbit[7]uril in aqueous solution. Org. Biomol. Chem. 11(3), 488-495 (2013).
63. Gamal-Eldin M.A., Macartney DH Cucurbit[7]uril host-guest complexes and [2] pseudorotaxanes with N-methylpiperidinium, N-methylpyrrolidinium, and N-methylmorpholinium cations in aqueous solution. Org. Biomol. Chem. 11(7), 1234-1241 (2013).
64. Glassenberg R. Reversing Succinylcholine Paralysis. Presented at: Anesthesiology 2011. IL, USA, 15-19 October 2011.
65. Glassenburg R, Avram M, McCarthy R. The effects of macrocycles on lidocaine seizures and succinylcholine fasciculations in mice. Presented at: Anesthesiology 2010. CA, USA, 16-20 October 2010.
66. Isaacs L. Cucurbit[n]urils: from mechanism to structure and function. Chem. Commun. 6, 619-629 (2009).
67. Isaacs L. The mechanism of cucurbituril formation. Isr. J. Chem. 51(5-6), 578-591 (2011).
68. Ma D, Zavalij P V, Isaacs L. Acyclic cucurbit[n] uril. cogeners are high affinity hosts. J. Org. Chem. 75(14), 4786-4795 (2010).
69. Lucas D, Isaacs L. Recognition properties of acyclic glycoluril oligomers. Org. Lett. 13 (15), 4112-4115 (2011).
70. Ma D, Hettiarachchi G, Nguyen D et al. Acyclic cucurbit[n]uril molecular containers enhance the solubility and bioactivity of poorly soluble pharmaceuticals. Nat. Chem. 4(6), 503-510 (2012).
71. Shen C, Ma D, Meany B., Isaacs L, Wang YH Acyclic cucurbit[n]uril molecular containers selectively solubilize single-walled carbon nanotubes in water. J. Am. Chem. Soc. 134(17), 7254-7257 (2012).
72. Minami T, Esipenko NA, Zhang B et al. Supramolecular sensor for cancer-associated nitrosamines. J. Am. Chem. Soc. 134(49), 20021-20024 (2012).
73. Ma D, Glassenberg R, Ghosh S., Zavalij PY, Isaacs L. Acyclic cucurbituril congener binds to localanaesthetics. Supramol. Chem. 24(5), 325-332 (2012).
74. Mock WL, Shih NY Structure and selectivity in host-guest complexes of cucurbituril. J. Org. Chem. 51(23), 4440-4446 (1986).
75. Nau WM, Florea M, Assaf KI Deep inside cucurbiturils: physical properties and volumes of their inner cavity determine the hydrophobic driving force for host-guest complexation. Isr. J. Chem. 51(5-6), 559-577 (2011).
76. Grosse-Sundrup M., Hoffmann U, Elamine L et al. New broad spectrum reversal agent for benzylisoquinoline and steroidal neuromuscular blocking agents. Presented at: Anesthesiology 2012. Washington, DC, USA, 13-17 October 2012.
77. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K et al. Calabadion: a new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology 119(2), 317-325 (2013).
78. Rodik RV, Boyko VL, Kalchenko VI Calixarenes in bio-medical researches. Curr. Med. Chem. 16(13), 1630-1635 (2009).
79. Perret F, Coleman AW Biochemistry of anionic calixarenes. Chem. Commun. 47(25), 7303-7319 (2011).
80. Nimse SB, Kim T. Biological applications of functionalized calixarenes. Chem. Soc. Rev. 42(1), 366-386 (2013).
81. Coleman AW, Jebors S, Cecillon S et al. Toxicity and biodistribution of para-sulfonato-calix[4]arene in mice. New J. Chem. 32(5), 780-782 (2008). (Pubitemid 351668103)
82. Da Silva E., Shahgaldian P, Coleman AW Haemolytic properties of some water-soluble para-sulphonato-calix[n]arenes. Int. J. Pharm. 273(1-2), 57-62 (2004). (Pubitemid 38317040)
83. Paclet M, Rousseau C, Yannick C., Coleman AW An absence of non-specific immune response towards para-sulphonato-calix[n]arenes. J. Incl. Phenom. Macrocycl. Chem. 55(3-4), 353-357 (2006). (Pubitemid 44127276)
84. Megyesi M, Biczok L. Considerable fluorescence enhancement upon supramolecular complex formation between berberine and p-sulfonated calixarenes. Chem Phys. Lett. 424(1-3), 71-79 (2006).
85. Megyesi M, Biczok L. Considerable change of fluorescence properties upon multiple binding of coralyne to 4-sulfonatocalixarenes. J. Phys. Chem. B. 114(8), 2814-2819 (2010).
86. Millership JS. A preliminary investigation of the solution complexation of 4-sulphonic calix[n]arenes with testosterone. J. Incl. Phenom. Macrocycl. Chem. 39(3-4), 327-331 (2001). (Pubitemid 33654917)
87. Dsouza RN, Pischel U, Nau WM Fluorescen dyes and their supramolecular host/guest complexes with macrocycles in aqueous solution. Chem. Rev. 111, 7941-7980 (2011).
88. Hu H, Rao Z, Xu J et al. 16-Morpholino quaternary ammonium steroid derivatives as neuromuscular blocking agents: synthesis, biological evaluation and in silico probe of ligand-receptor interaction. Eur. J. Med. Chem. 56, 332-347(2012).
89. Gyermek L. Development of ultra short-acting muscle relaxant agents: history, research strategies, and challenges. Med. Res. Rev. 25(6), 610-654 (2005). (Pubitemid 41447146)
90. Gyermek L, Lee C. The development of ultrashort acting neuromuscular relaxant tropane derivatives. J. Crit. Care. 24(1), 58-65 (2009).
91. Lien CA, Savard P, Belmont M., Sunaga H, Savarese JJ Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J. Crit. Care 24 (1), 90-97 (2009).
92. Savarese JJ, McGilvra JD, Sunaga H et al. rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology 113(1), 58-73 (2010).
93. Sunaga H, Malhotra, JK, Yoon E et al. Cysteine reversal of the novel neuromuscular blocking drug cw002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology. Anesthesiology 112(4), 900-909 (2010).
94. Sunaga H, Zhang Y, Savarese J.J., Ernala CW Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology 112(4), 892-899 (2010).
95. European Medicines Agency - Bridion. www.emea.europa.eu/ema/index.jsp? curl=pages/human/medicines/000885/human-med-000680.jsp (Accessed 3 May 2013)
96. Sugammadex FDA Approval Status. www.drugs.com/history/sugammadex.html (Accessed 3 May 2013)
97. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the incidence of hypersensitivity after repeated single dose administrations of sugammadex in healthy subjects. Study P06042. http://clinicaltrials.gov/ct2/show/NCT00988065?term=sugammadex&rank=3 (Accessed 7 May 2013)